An Open-Label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-Release to Extended-Release Formulation and Vice Versa
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Lamotrigine (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 23 Jan 2018 Results assessing the effect of Age-Related Factors on the PK of Lamotrigine and Potential Implications for Dose Optimisation in patients data obtained from NCT00043875, NCT00144872, NCT00113165, NCT00104416, NCT00516139, NCT00264615 published in the Clinical Pharmacokinetics
- 15 Oct 2008 Actual start date changed from Aug 2005 to Oct 2005 as reported by clinicalTrials.gov.
- 14 Oct 2008 Trial phase changed from II/III to III as reported by ClinicalTrials.gov.